Correlation between lipidic content and arterial-wall plaque burden: A Lipid Rich Plaque study sub-analysis

Int J Cardiol. 2022 Nov 1:366:32-34. doi: 10.1016/j.ijcard.2022.07.024. Epub 2022 Jul 13.

Abstract

Background: Large plaque burden (PB) has been linked to adverse coronary events. We sought to assess the correlation between lipidic content and arterial PB within the Lipid Rich Plaque (LRP) study.

Methods: This analysis included 1269 patients and 5743 coronary segments with both evaluable Lipid Core Burden Index (maxLCBI4mm) and PB. Non-culprit major adverse cardiac events (NC-MACE; defined as a composite of cardiac death, cardiac arrest, non-fatal myocardial infarction, acute coronary syndrome, revascularization, and hospital readmission for angina with progressive stenosis) were assessed by hazard ratios (HR) at 2 years.

Results: NC-MACE for segment cohorts in the most vulnerable quadrant of maxLCBI4mm > 400 and PB >40% was the highest (HR, 3.78 [95% confidence interval (CI) 2.39-5.66]) with similar rates for just PB >40% (HR 1.31 [95% CI 0.81-2.02]) and just maxLCBI4mm > 400 (HR 1.11 [95% CI 0.10-5.38]). Fewer events occurred in the maxLCBI4mm ≤ 400 and PB ≤40% quadrant (HR 0.25 [95% CI 0.11-0.50]).

Conclusions: Coronary segments with high lipid content but no measurable PB were still associated with events at 2 years. NC-MACE vulnerability increased as the lipidic content and PB increased, with the highest incidence within segments having maxLCBI4mm > 400 and plaque >40%.

Clinical trial registration: The Lipid-Rich Plaque Study (LRP), NCT02033694, https://clinicaltrials.gov/ct2/show/NCT02033694.

Keywords: Coronary artery disease; Intravascular imaging; Lipid core burden index; Lipid-rich plaque; Plaque burden.

Publication types

  • Clinical Study

MeSH terms

  • Coronary Angiography
  • Coronary Artery Disease* / complications
  • Coronary Artery Disease* / diagnosis
  • Coronary Artery Disease* / epidemiology
  • Coronary Vessels / diagnostic imaging
  • Humans
  • Lipids
  • Plaque, Atherosclerotic* / complications
  • Predictive Value of Tests
  • Spectroscopy, Near-Infrared
  • Ultrasonography, Interventional

Substances

  • Lipids

Associated data

  • ClinicalTrials.gov/NCT02033694